RedHill Biopharma: Funding, Investors & Team (Sep 2026)
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
RedHill Biopharma has raised $42.3M across 7 funding rounds on record, the most recent an undisclosed round of $6.0M announced in Jun 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
RedHill Biopharma Company Profile and Key Stats
Latest funding round on record: Jun 2026.
RedHill Biopharma Funding Rounds
1 of 7 rounds was announced without a disclosed amount and is excluded from the total.
RedHill Biopharma raised $15.0M in a Post-IPO Equity announced in May 2022.
7 months later, an undisclosed round of $8.0M was announced in Dec 2022.
1.1 years later, an undisclosed round of $8.0M was announced in Jan 2024.
3 months later, an undisclosed round of $1.3M was announced in Apr 2024.
6 months later, an undisclosed round was announced in Oct 2024 with no disclosed amount.
1 years later, an undisclosed round of $4.0M was announced in Oct 2025.
8 months later, an undisclosed round of $6.0M was announced in Jun 2026.
RedHill Biopharma Founders and Leadership Team
Contact details for the RedHill Biopharma team: 2 of 3 have an email address on file.
Start 14-day free trial →RedHill Biopharma Funding Compared to Other Biotechnology Startups
RedHill Biopharma's latest round of $6.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like RedHill Biopharma in Biotechnology and Tel Aviv
Companies Similar to RedHill Biopharma
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
NeuroSense Therapeutics Ltd., is a clinical-stage biotechnology company, dedicated to the discovery and…
RedHill Biopharma Funding FAQs
What does RedHill Biopharma do?
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
How much funding has RedHill Biopharma raised?
RedHill Biopharma has raised $42.3M across 7 rounds on record. The most recent is an undisclosed round of $6.0M announced in Jun 2026.
When did RedHill Biopharma last raise funding?
RedHill Biopharma's most recent funding round on record is an undisclosed round of $6.0M, announced in Jun 2026.
Who founded RedHill Biopharma?
FundedIQ lists Dror Ben Asher (Founder), Kel Sheldon (Founder) at RedHill Biopharma.
Who is the CEO of RedHill Biopharma?
Ori Shilo is listed as CEO at RedHill Biopharma.
Where is RedHill Biopharma headquartered?
RedHill Biopharma is based in Tel Aviv, Israel.
How many employees does RedHill Biopharma have?
RedHill Biopharma is in the 101-250 employee band.
How does RedHill Biopharma's funding compare to other Biotechnology startups?
RedHill Biopharma's latest round of $6.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's RedHill Biopharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for RedHill Biopharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.